# Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)

> **NCT03131726** · PHASE3 · RECRUITING · sponsor: **Lund University** · enrollment: 80 (estimated)

## Conditions studied

- Graves Ophthalmopathy
- Thyroid Associated Ophthalmopathy
- Thyroid Associated Orbitopathy

## Interventions

- **DRUG:** Simvastatin 40mg

## Key facts

- **NCT ID:** NCT03131726
- **Lead sponsor:** Lund University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-01-26
- **Primary completion:** 2027-01-26
- **Final completion:** 2028-03-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03131726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03131726, "Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03131726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*